{
  "title": "2.0 Clinical Data (MM1) Study",
  "hero": {
    "background": {
      "mobile": "images/hero-bg--mobile.png",
      "desktop": "images/hero-bg--desktop.png"
    },
    "title": "<strong>NINLARO<sup>&reg;</sup> (ixaomib) Mechanism of Action</strong>"
  },
  "referenceList": "<ul><li><strong>Primary endpoint:</strong> PFS, according to 2011 IMWG criteria, was assessed every 4 weeks until disease progression by a blinded IRC and was based on central laboratory results<sup>1,2</sup></li><li><strong>Key secondary endpoints:</strong> OS and OS in del(17p)<sup>1,2</sup></li><li><strong>Other secondary endpoints:</strong> ORR and PFS in patients with high-risk cytogenetics§ and safety<sup>1,2</sup></li></ul>",
  "referenceText": "<p>†Defined as treatment to disease progression or unacceptable toxicity.<br /> ‡Stratification 1 vs 2 or 4 prior therapies; PI exposed vs PI naive; and ISS stage I or II vs III.</p>",
  "twoCards": [
    {
      "class": "card--enclosed",
      "title": "NINLARO dosing",
      "description": "<p>Find the dosing schedule for the NINLARO all-oral triple regimen and information on dose modifications.</p>",
      "cta": {
        "url": "#test",
        "text": "Get Dosing Info",
        "icon": "icon-chevron-right"
      }
    },
    {
      "class": "card--enclosed",
      "title": "NINLARO real-world studies",
      "description": "<p>Real-world evidence can help bridge the gap between clinical trials and clinical practice.</p>",
      "cta": {
        "url": "#test",
        "text": "Get Real-World Study Results",
        "icon": "icon-chevron-right"
      }
    }
  ]
}